Bruker Corporation (NASDAQ:BRKR) shares reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $31.41 and last traded at $31.41, with a volume of 426,660 shares. The stock had previously closed at $30.76.
Several research analysts have recently issued reports on the company. BidaskClub cut Bruker Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Cowen and Company reaffirmed a “hold” rating and set a $29.00 price objective on shares of Bruker Corporation in a research report on Friday, July 14th. Barclays PLC reaffirmed an “equal weight” rating and set a $30.00 price objective (up from $26.00) on shares of Bruker Corporation in a research report on Monday, July 17th. Zacks Investment Research raised Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research report on Thursday, July 6th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and set a $24.00 price objective on shares of Bruker Corporation in a research report on Tuesday, September 26th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $26.70.
The firm’s 50 day moving average is $30.14 and its 200-day moving average is $27.92. The stock has a market capitalization of $5.04 billion, a price-to-earnings ratio of 31.64 and a beta of 1.09.
Bruker Corporation (NASDAQ:BRKR) last issued its earnings results on Thursday, August 3rd. The medical research company reported $0.23 EPS for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.03. Bruker Corporation had a return on equity of 26.66% and a net margin of 9.65%. The company had revenue of $414.90 million during the quarter, compared to the consensus estimate of $384.75 million. During the same period in the previous year, the firm posted $0.20 earnings per share. Bruker Corporation’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, analysts anticipate that Bruker Corporation will post $1.12 earnings per share for the current fiscal year.
In other Bruker Corporation news, VP Mark Munch sold 21,061 shares of Bruker Corporation stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total value of $631,198.17. Following the completion of the transaction, the vice president now directly owns 60,524 shares in the company, valued at $1,813,904.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Frank H. Laukien bought 2,335 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was bought at an average price of $27.39 per share, with a total value of $63,955.65. Following the completion of the purchase, the chief executive officer now owns 37,791,386 shares of the company’s stock, valued at $1,035,106,062.54. The disclosure for this purchase can be found here. Insiders own 35.20% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Acrospire Investment Management LLC boosted its stake in Bruker Corporation by 496.1% in the second quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock valued at $110,000 after acquiring an additional 3,185 shares during the period. SG Americas Securities LLC acquired a new position in Bruker Corporation in the second quarter valued at approximately $111,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Bruker Corporation by 11.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock valued at $133,000 after acquiring an additional 467 shares during the period. Smithfield Trust Co. acquired a new position in Bruker Corporation in the second quarter valued at approximately $138,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Bruker Corporation by 7.1% in the second quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock valued at $144,000 after acquiring an additional 331 shares during the period. Institutional investors own 65.44% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Bruker Corporation (BRKR) Sets New 12-Month High at $31.41” was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/10/29/bruker-corporation-brkr-sets-new-12-month-high-at-31-41.html.
Bruker Corporation Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
What are top analysts saying about Bruker Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bruker Corporation and related companies.